GlobeNewswire

New fNIR Technology Sheds Light on Brain Activity with Powerful Imagers for Real-world Situations

Del

Systems offer comfort and mobility to measure human subjects in the lab, at home, or in the real world

GOLETA, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BIOPAC Systems, Inc., the global distributor for fNIR Devices, announced the availability of its newest generation of functional near infrared optical imaging (fNIR) systems. The new high-density imaging systems provide in-lab or real-world cognitive function assessments for physiology researchers looking to understand brain activity without all the expense of fMRI. 

The extra-lightweight sensor fits comfortably on the forehead where it monitors relative changes in oxy or deoxy hemoglobin as a proxy for the brain activity in the pre-frontal cortex. Subjects can be examined in laboratory settings or they can be active in their natural environment with the new mobile fNIR system.

The new NIRS systems offer three powerful imagers. The fNIR 2000C is a stationary unit that collects data from up to 18 optodes. The fNIR 2000M is a wireless and mobile imager that collects data from up to 18 optodes and can be used while subjects are performing tasks in the lab or in the real world. The fNIR 2000S is a 54-optode capable imager with advanced features for recording up to three subjects simultaneously.

A new through-the-hair sensor will allow researchers to assess other areas of the brain such as motor and visual cortices. Adding in different parts of the brain increases understanding of brain activity without the complications of fMRI.

All systems include fNIRSoft and COBI software for data collection and analysis. Data can be synchronized with and imported into AcqKnowledge Software for a complete understanding of physiological response, including EEG, EDA, ECG, BP, and other important physiology signals.

“Experimental design can be more sophisticated with this mobile technology. It gives researchers the opportunity to collect data from subjects as they live their lives.” said Frazer Findlay, BIOPAC’s CEO. “Mobile imaging can add value to any study but is especially important when subjects are children or families, as they can be in a familiar or comfortable environment, yielding better results.”

 “When designing and manufacturing fNIR Devices, we decided not to weigh down the subject’s head with a battery and extra electronics. As a result, our imagers, including our wireless imager, measure the brain’s hemodynamic response with minimal weight and maximum comfort.” said Davood Tashayyod, fNIR Devices CEO. “fNIR Devices systems are very easy to set up and very comfortable for the subject. A comfortable subject produces better quality data  and can participate in short- and long-term studies.”

fNIR and NIR imaging are citied in over 132,000 publications. NIR applications include Brain Computer Interface, Human Performance Assessment, Neurorehabilitation, Depth of Anesthesia Monitoring, and more. fNIR technology can also be used to understand blood oxygenation of muscles.

Contact BIOPAC for more information about using fNIR technology for measuring mobile subjects in real-world situations, stationary subjects in a lab, or when teaching students in an educational environment.

About BIOPAC Systems

BIOPAC was founded in 1985 and is recognized around the world as a premier choice for life science hardware and software. Worldwide, over 99% of the top 100 universities and Global Fortune 500 companies rely on BIOPAC systems for their life science research and teaching system needs. BIOPAC makes high-quality scientific tools for physiology measurement and interpretation. BIOPAC solutions range from educational solutions to cutting-edge devices for use in lab, real world, and virtual reality research environments. For more information on BIOPAC products, visit www.biopac.com.

About fNIR Devices

Founded in 2009, fNIR Devices, LLC, is the premier supplier of Continuous Wave Functional Near Infrared (fNIR) Spectroscopy imaging systems for research and other non-clinical applications. fNIR Devices provide physiology researchers with robust and meticulously crafted systems for monitoring the brain’s hemodynamics, thereby understanding the subject’s cognitive state in both lab and natural environments.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ea24834a-8a45-4d6c-a5d8-46271fa5f249

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Tenaris to Acquire IPSCO Tubulars from TMK22.3.2019 13:58:00 CETPressemelding

LUXEMBOURG, March 22, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announced today that it has entered into a definitive agreement to acquire from PAO TMK, a Russian company and manufacturer of steel pipe, 100% of the shares of its wholly owned U.S. subsidiary IPSCO Tubulars, Inc., for US$1,209 million, on a cash-free, debt-free basis, which includes US$270 million of working capital. The transaction is subject to regulatory approvals, including approval by the U.S. antitrust authorities, and other customary conditions. IPSCO Tubulars is a U.S. domestic producer of seamless and welded OCTG and line pipe products, with an annual production capacity of 450,000 metric tons of steel bars, 400,000 metric tons of seamless pipe and 1,000,000 metric tons of welded pipe, and production facilities spread throughout the country. The acquisition would enhance Tenaris’s position and local manufacturing presence in the U.S. market, extending its produc

Oxford Immunotec Announces Chief Financial Officer Transition21.3.2019 21:01:00 CETPressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Richard Altieri, the Company’s Chief Financial Officer (CFO), will retire on April 30, 2019. The Company has appointed Matthew McLaughlin, currently Chief Financial Officer, GE Healthcare – U.S. and Canada, as his successor. Mr. McLaughlin will join Oxford Immunotec as CFO on April 8, 2019. Today’s announcement concludes an extensive search process conducted by the Company. As part of the planned succession, Mr. Altieri, who has led Oxford Immunotec’s global finance organization as CFO since 2012, will remain an active member of the Company’s management team until his retirement date. “During his seven year tenure, Rick successfully managed multiple financing rounds, including the Company's IPO, the acquisition and financial integration of three companies and, most recently, the dives

Blackhawks, Flyers, Sabres and Lightning Headline the 2019 NHL Global Series21.3.2019 15:34:00 CETPressemelding

Chicago Blackhawks and Philadelphia Flyers to Open Regular Season in Prague, Czech Republic on Oct. 4 Buffalo Sabres and Tampa Bay Lightning to Face Off in a Pair of Games in Stockholm, Sweden on Nov. 8 and Nov. 9 2019 NHL Global Series Challenge to feature Blackhawks vs. Eisbären Berlin on Sept. 29 in Berlin, Germany and Flyers vs. Lausanne HC on Sept. 30 in Lausanne, Switzerland Tickets to Games in Berlin, Prague and Stockholm Available for Purchase on Wednesday, March 27; Tickets to Game in Lausanne Available for Purchase on Wednesday, April 10 NEW YORK/TORONTO, March 21, 2019 (GLOBE NEWSWIRE) -- The National Hockey League (NHL) and the National Hockey League Players’ Association (NHLPA), in conjunction with Live Nation Sweden, today announced that the Buffalo Sabres, Chicago Blackhawks, Philadelphia Flyers and Tampa Bay Lightning will participate in the 2019 NHL Global Series. The Chicago Blackhawks and Philadelphia Flyers will play their 2019-20 season-opening game against each ot

Farmako: World's Largest Import Contract for Pharmaceutical Cannabis21.3.2019 15:10:00 CETPressemelding

German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska FRANKFURT, March 21, 2019 (GLOBE NEWSWIRE) -- Farmako will import 50 tonnes of pharmaceutical cannabis from Pharmacann Polska into the European market over the next four years. This provides the basis for a reliable supply of pharmaceutical cannabis for millions of patients in the European healthcare system. The company expects a total revenue of several hundred million Euros from the agreed exclusive partnership. Founded in September 2018, Farmako now has grown to 40 employees and is distributing high-quality pharmaceutical cannabis to German pharmacies since March 2019. This is the biggest Cannabis contract to date, and the first big contract without participation of a Canadian LP. Farmako has signed an exclusive and binding agreement to import and distribute 50 tons of pharmaceutical cannabis over four years. Farmako and Pharmacann Polska enter strategic partnership to develop custom tailored

NexOptic Appoints Rich Geruson, Former Lexmark CEO, to Board of Directors21.3.2019 14:00:00 CETPressemelding

VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1) is pleased to announce that Richard J. (Rich) Geruson has joined its Board of Directors, effective immediately. Mr. Geruson’s experience spans CEO roles at Lexmark International, Phoenix Technologies and VoiceSignal Technologies, and Senior Vice President and executive positions at Nokia, IBM, Toshiba, and McKinsey & Co. As CEO of Lexmark International, a multibillion-dollar imaging technology and solutions company with 10,000 employees, he grew printer sales faster than at any time in the preceding 10 years while simultaneously executing extensive process reengineering, transforming the business from negative EBITDA and high debt to positive multi-hundred-million-dollar EBITDA and a healthy debt profile. While CEO of Phoenix Technologies, he achieved consistently high profit year-over-year for six years straight in